Johnson & Johnson announces a $2 billion North Carolina manufacturing expansion as part of a broader U.S. onshore ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Sure, nobody goes around boasting, "We're Number Two!" But in certain circumstances, coming in second has its advantages.

Eli Lilly & Co ( ($LLY) ) has provided an announcement. On August 18, 2025, Eli Lilly & Co entered into an underwriting ...

Indianapolis: Eli Lilly and Company has announced that Anne White, executive vice president and president, Lilly Neuroscience ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks to watch as Jim Cramer looked at market rationality. Cramer discussed ...

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

With the price of Mounjaro set to almost triple in the UK, there are fears more and more people will turn to counterfeits.

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

S&P 500, Eli Lilly and Company, Nomura Holdings Inc ADR, The Health Care Select Sector SPDR® Fund. Read 's Market Analysis on Investing.com ...